Market Overview

UPDATE: Wedbush Cuts PT to $54 on Vitamin Shoppe on Reduced Guidance

Related VSI
Vitamin Shoppe Downgraded At JPMorgan As Industry Loses Muscle
Barclays Shrugs At Food & Staples Sector, Interest Piqued By Just 3 Names
Vitamin Shoppe: Close To 6 Year Lows With Potential Upside (Seeking Alpha)

Wedbush maintained Vitamin Shoppe (NYSE: VSI) with a Neutral rating and lowered the price target from $59.00 to $54.00.

Wedbush said, "A reduction in 2013 guidance for new store openings to 50 from 57, due to co-tenants in certain development projects delaying signing leases, keeping builders from beginning work on the projects, is concerning for a unit-growth story such as VSI. Given the delays, new store openings are 2H loaded (new store openings: 20 1H; 30 2H). … Given unit growth and consistent MSD SSS growth, we believe shares of VSI should trade at an EV/2013E EBITDA multiple of 10.5x, a 20% premium to other mid-cap healthy lifestyle firms."

Vitamin Shoppe closed at $50.79 on Monday.

Latest Ratings for VSI

Oct 2016JP MorganDowngradesOverweightNeutral
Sep 2016BarclaysInitiates Coverage onEqual-Weight
Apr 2016WedbushInitiates Coverage onOutperform

View More Analyst Ratings for VSI
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings


Related Articles (VSI)

View Comments and Join the Discussion!